Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE000A1EWVY8
Fri, 17.06.2022
Formycon AG
Press Release // June 17, 2022
Formycon publishes Update on Development Projects
- FYB201/ONGAVIA®1 is expected to be the first biosimilar to Lucentis®2 to be commercialized in Europe
- EMA and FDA approvals for Lucentis® biosimilar FYB201 anticipated in Q3/2022
- FYB202: Treatment of all patients in phase III clinical trial completed (last [ … ]
Thu, 19.05.2022
Formycon AG
Press Release // May 19, 2022
Formycon appoints Dr. Stefan Glombitza as CEO and sets the course for the future by appointing the two experienced pharmaceutical managers Nicola Mikulcik and Dr. Andreas Seidl to the Executive Board
- Long-standing Chief Operating Officer (COO) Dr. Stefan Glombitza takes over the position of Chief Executive Offi [ … ]
Thu, 19.05.2022
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // May 19, 2022
Formycon announces changes to its Executive Board
Munich – Today and effective July 1, 2022, the Supervisory Board of Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) ("Formycon") appointed Dr. Stefan Glombitza, wh [ … ]
Wed, 18.05.2022
Formycon AG
Press Release // May 18, 2022
Formycon Publishes Annual Financial Statements for the 2021 Financial Year
- Group turnover and other earnings total Euro 41.7 million
- Liquidity solid at a total of EUR 36.2 million
- Annual result shaped by scheduled investments in FYB202, FYB206 and FYB207
- Conversion of Group reporting to IFRS as of the 2 [ … ]
Tue, 17.05.2022
Formycon AG
Press Release // May 17, 2022
United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) grants Marketing Authorization for FYB201, Formycon's Biosimilar for Lucentis®1, to be Commercialized by Teva as ONGAVIA®
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Bioeq AG (“Bioeq”) announce, that today the [ … ]
Tue, 17.05.2022
Formycon AG
Publication of insider information in accordance with Article 17 of the Regulation (EU) No 596/2014 Ad Hoc Announcement // May 17, 2022
FYB201, Formycon's Biosimilar for Lucentis®1 achieves Marketing Authorization in United Kingdom
Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Bioeq AG (“Bioeq”) announce, that tod [ … ]
Tue, 10.05.2022
Formycon AG
Press Release // May 10, 2022
Formycon AG and ATHOS KG announce closing of transaction to acquire biosimilar assets FYB201 and FYB202 as well as Bioeq GmbH
- Full acquisition of biosimilar candidate FYB202 (ustekinumab) and acquisition of a 50% stake in biosimilar candidate FYB201 (ranibizumab) completed
- Takeover of the operational developm [ … ]
Thu, 14.04.2022
Formycon AG
First Berlin Equity Research hat ein Research Update zu Formycon AG (ISIN:
DE000A1EWVY8) veröffentlicht. Analyst Simon Scholes bestätigt seine
BUY-Empfehlung und erhöht das Kursziel von EUR 78,00 auf EUR 89,00.
Zusammenfassung:
Formycon hat eine €650 Mio.-Transaktion mit dem Unternehmen Athos KG der
Gebrüder Strüngm [ … ]
Tue, 29.03.2022
Formycon AG
Press Release // March 29, 2022
Formycon is acquiring the biosimilar assets FYB201 and FYB202 and strengthening its position in the global growth market of biosimilars through long-term partnership with ATHOS KG
- Total value of transaction volume approximately Euro 650 million
- Complete acquisition of biosimilar candidate FYB202 (ustekinumab) [ … ]
Tue, 29.03.2022
Formycon AG
Publication of insider information in accordance to Article 17 of Regulation (EU) No. 596/2014Ad Hoc Announcement // March 29, 2022
Formycon and ATHOS KG merge development activities through the acquisition of biosimilar assets in a long-term strategic partnership
Munich - Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) ("Formycon") and ATHOS KG ( [ … ]